News

Ideas That Generate Results

The market for non-invasive prenatal diagnostics tests in the US is currently dominated by Sequenom as it got the first mover advantage in the industry. With around 50% market share in terms of volume, Sequenom boasts of having effective marketing strategies that seek to encourage US physicians to recommend its MaterniT21 plus test. In terms of value, Sequenom will remain the market leader in 2018 as well accounting for over 45% of the total market share.
 
Our latest research report “US Non-Invasive Prenatal Testing Market Outlook 2018”, provides a prudent analysis on the current and future size of the market weighing the possible pessimistic and optimistic scenarios. In addition to it, the report has even mentioned the potential market for high and medium to high risk pregnancy patients. The demographic scenario of United States has been discussed with focus on the current and future number of births, with the demographics segregated by age and state.
 
It also provides a transparent view on the present regulatory framework elaborating on the existing loopholes. Our report has discussed the views of regulatory authorities, players and consumers towards the regulatory stringency and the direction of regulations in the future have also been covered.
 
Currently, the US NIPT sector is characterized by the presence of players like Sequenom, Verinata, Ariosa and Natera. These players have been profiled with their strengths and weaknesses and latest developments in the field of NIPT. The report is a must buy for new market entrants in the diagnostics field, planning to enter the prenatal segment.
 
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM668.htm
 
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm